ZZZhijian Zhang

Zhijian Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhijian Zhang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Lin

    Shanghai General Hospital, Shanghai, China

    2 shared publications
  • Yong-De Peng

    Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Andrew S. Rhinehart

    Medtronic Diabetes, 19784, Clinical Research & Medical Science, Northridge, California, United States;

    1 shared publication
  • Caizhi Liu

    Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

    1 shared publication
  • Chuanhao Xiong

    Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China

    1 shared publication
  • Fang Liu

    Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 201620, China

    1 shared publication

Latest Publications

  • Open Access

    Leupaxin promotes hepatic gluconeogenesis and glucose metabolism by coactivation with hepatic nuclear factor 4α

    by Xiaomin Luo, Fang Liu, Lijun Zhu, Caizhi Liu, Ruhui Shen, Xiaoyin Ding, Yufan Wang, Xiaofang Tang, Yongde Peng, Zhijian Zhang


  • Open Access

    The role of total bilirubin in bone mineral density among patients with type 2 diabetes older than 50 years

    by Xiao-Min Luo, Min Tang, Xiao-Hui Wei, Neng-Guang Fan, Zhi-Jian Zhang, Yong-De Peng

    Background: Bilirubin may exert antioxidant and cytoprotective effects by scavenging peroxyl radicals and inhibiting oxidation. There is evidence that middle-aged and elderly patients with type 2 diabetes mellitus (T2DM) have abnormal bone metabolism and deterioration of bone microstructure, which can easily lead to increased bone fragility and osteoporosis. However, few studies have reported whether total bilirubin (TB) is associated with bone metabolism in middle-aged and elderly T2DM patients. We collected 10 years of data from the NHANES database to examine the association between TB and bone mineral density (BMD) in the US population of T2DM patients older than 50 years. Methods: The population data in this study were obtained from five cycles of the NHANES database (2005-2006, 2007-2008, 2009-2010, 2013-2014, and 2017-2018) with a total of 50,464 subjects. The outcomes of interest were total femur BMD and lumbar BMD. The relationship between TB and BMD was analyzed using weighted multiple linear regression, subgroup analysis, generalized additive models, smoothed fitted curves, and two-part logistic regression. Results: A total of 1609 individuals (mean age 63.78 years; 60.99% Caucasian) were available for final data analysis based on strict eligibility criteria. After complete correction for potential confounders, no association was found between TB and BMD. However, in other racial populations (mainly non-Hispanic Asians), TB levels were positively associated with both BMDs [total femur BMD, β (95% CI), 0.005 (0.000, 0.010); lumbar BMD, β(95% CI), 0.005 (0.000, 0.009)]. In addition, no interactions were observed based on all priori stratification. Conclusions: This study demonstrates that TB levels are not associated with BMD when the effect of underlying liver disease is excluded in a nationally representative population of T2DM over 50 years of age in the United States. However, in Asian populations, TB levels appear to be positively associated with BMD.

  • Open Access

    Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus

    by Yu Pei, Weijian Ke, Jing Lu, Yi Lin, Zhijian Zhang, Yongde Peng, Yan Bi, Yanbing Li, Jue Hou, Xiaolu Zhang, et al.

    Background: While evidence supports glycemic control benefits for individuals with type 1 diabetes mellitus (T1DM) using hybrid closed-loop (HCL) systems, HCL automated insulin delivery therapy in China has not been assessed. This study evaluated safety events and effectiveness during HCL system use by Chinese adolescents and adults with T1DM. Methods: Sixty-two participants ( n = 12 adolescents with a mean ± standard deviation [SD] of 15.5 ± 1.1 years and n = 50 adults [mean ± SD of 37.6 ± 11.1 years]) with T1DM and baseline A1C of 7.1% ± 1.0% underwent a run-in period (∼2 weeks) using open-loop Manual Mode (sensor-augmented pump) insulin delivery with the MiniMed™ 770G system with the Guardian™ Sensor (3) glucose sensor, followed by a study period (4 weeks) with HCL Auto Mode enabled. Analyses compared continuous glucose monitoring data and insulin delivered during the run-in versus study period (Wilcoxon signed-rank test or t -test). Safety events included rates of severe hypoglycemia and diabetic ketoacidosis (DKA). Results: Compared to baseline run-in, overall Auto Mode use increased time in range (TIR, 70–180 mg/dL) from 75.3% to 80.9% ( P < 0.001) and reduced time below range (TBR, P < 0.001). Subgroup analysis demonstrated that participants ( n = 29) with baseline A1C 180 mg/dL) that reduced from 31.6% to 20.8%. Auto Mode use also increased the percentage achieving combined recommendations for time at sensor glucose ranges (i.e., TIR of >70%, TBR of P = 0.013). There were no severe hypoglycemic, DKA, or serious adverse events. Conclusions: Chinese adolescents and adults, some of whom met target A1C at baseline, safely achieved significantly improved glycemia with 1 month of MiniMed 770G system use when compared to open-loop insulin delivery. ClinicalTrials.gov ID: NCT04663295.


  • Open Access

    Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue

    by Yahui Zhang, Yi Lin, Guoqiang Li, Yuan Yuan, Xuejiao Wang, Na Li, Chuanhao Xiong, Yueying Yang, Yuhang Ma, Zhijian Zhang, et al.

    Polycystic ovary syndrome is a complicated hormonal and metabolic disorder. The exact pathogenesis of polycystic ovary syndrome is not clear thus far. Inflammation is involved in the progression of polycystic ovary syndrome. In addition, brown adipose tissue activity is impaired in polycystic ovary syndrome. Interestingly, glucagon-like peptide-1 receptor agonists have been reported to alleviate inflammation and promote browning of white adipose tissue. In this study, the effects of glucagon-like peptide-1 receptor agonists on polycystic ovary syndrome mice were explored. Mice were randomly assigned into four groups: control, dehydroepiandrosterone, dehydroepiandrosterone + liraglutide, and dehydroepiandrosterone + semaglutide. Relative indexes were measured after glucagon-like peptide-1 receptor agonist intervention. Glucose metabolism in polycystic ovary syndrome mice was ameliorated by glucagon-like peptide-1 receptor agonists, while the reproductive endocrine disorder of polycystic ovary syndrome mice was partially reversed. The messenger ribonucleic acid levels of steroidogenic enzymes and the expression of inflammatory mediators in serum and ovaries of polycystic ovary syndrome mice were improved. Furthermore, toll-like receptor 4 and phosphorylation of nuclear factor-kappa B protein levels were decreased by glucagon-like peptide-1 receptor agonists in ovary. Notably, after glucagon-like peptide-1 receptor agonist intervention, the expression of brown adipose tissue marker levels was considerably raised in the white adipose tissue of polycystic ovary syndrome mice. In conclusion, the hyperinsulinemia and hyperandrogenemia of polycystic ovary syndrome mice were alleviated by glucagon-like peptide-1 receptor agonist intervention, which was associated with mitigating inflammation and stimulating adipose tissue browning.